Glenmark Pharmaceuticals Ltd.

<body bgcolor="#FFFFFF" text="#000000"> April 27, 2005 Glenmark Pharma posts 60.96% revenue growth and 169.31% net profit growth for FY05 April 26, 2005 Glenmark Pharmaceuticals Announces Receipt of First Milestone from Forest Laboratories Inc. on Successful Completion of Phase I Clinical Trials on its PDE4 Inhibitor for Asthma and COPD April 26, 2005 Glenmark Pharmaceuticals and Teijin Pharma Limited Announce Collaboration Agreement on PDE4 Inhibitor for Asthma and COPD for the Territory of Japan </body>